Biodelivery Sciences International Inc. (BDSI), of Raleigh, N.C., entered an assignment and revenue-sharing agreement with Meda AB, of Stockholm, under which Meda will transfer the marketing authorizations for Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain in the U.S. and the right to seek marketing authorizations for the product in Canada and Mexico back to BDSI, which originally licensed the rights to Meda in 2007.